关键词: 晚期乳腺癌, HER2阴性

Abstract:

Interpretation of the ASCO practice guideline：Chemotherapy and targeted for women with HER2-Negative (or unknown) advanced breast cancer              GAO Guo-xuan，LIU Yin-hua.Breast Disease Center，Peking University First Hospital，Beijing 100034，China
Corresponding author：LIU Yin-hua，E-mail：liuyinhua@medmail.com.cn
Abstract    In October 2014 Journal of Clinical Oncology，it published the Chemotherapy and Targeted for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer：ASCO Practice Guideline.Recommendations include：Endocrine therapy is preferable to chemotherapy as first-line treatment for patients with estrogen receptor-positive metastatic breast cancer unless improvement is medically necessary (eg，immediately life-threatening disease).Single agent is preferable to combination chemotherapy，and longer planned duration improves outcome but must be balanced against toxicity.There is no single optimal first-line or subsequent line chemotherapy，and choice of treatment will be determined by multiple factors including prior therapy，toxicity，performance status，comorbid conditions，and patient preference.The role of bevacizumab remains controversial.Other targeted therapies have not so far been shown to enhance chemotherapy outcome in HER2-negative breast cancer.

Key words: advanced breast cancer, HER2-negative